DVOŘÁK, Petr, Pavel KREJČÍ, Lukáš BÁLEK, Lívia EISELLEOVÁ, Žaneta KONEČNÁ, Pavel DVOŘÁK, David BEDNÁŘ, Jan BREZOVSKÝ, Eva ŠEBESTOVÁ, Radka CHALOUPKOVÁ, Veronika ŠTĚPÁNKOVÁ, Pavel VAŇÁČEK, Zbyněk PROKOP, Jiří DAMBORSKÝ and Michaela BOSÁKOVÁ. Thermostable FGF2 polypeptide, use thereof. 2021.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Thermostable FGF2 polypeptide, use thereof
Authors DVOŘÁK, Petr (203 Czech Republic, belonging to the institution), Pavel KREJČÍ (203 Czech Republic, belonging to the institution), Lukáš BÁLEK (203 Czech Republic, belonging to the institution), Lívia EISELLEOVÁ (703 Slovakia, belonging to the institution), Žaneta KONEČNÁ (203 Czech Republic, belonging to the institution), Pavel DVOŘÁK (203 Czech Republic, belonging to the institution), David BEDNÁŘ (203 Czech Republic, belonging to the institution), Jan BREZOVSKÝ (203 Czech Republic, belonging to the institution), Eva ŠEBESTOVÁ (203 Czech Republic, belonging to the institution), Radka CHALOUPKOVÁ (203 Czech Republic, belonging to the institution), Veronika ŠTĚPÁNKOVÁ, Pavel VAŇÁČEK, Zbyněk PROKOP, Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution) and Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution).
Edition Number: AU2016359722, Publisher: Australian Patent Office, Place of publication: Australia, Owner's name: Masarykova Univerzita; Enantis s.r.o. 2021.
Other information
Original language English
Type of outcome Patent
Field of Study 10600 1.6 Biological sciences
Country of publisher Australia
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14310/21:00124498
Organization unit Faculty of Science
Keywords in English FGF2; Stem cells; Drugs
Tags International impact
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 7/4/2022 14:09.
Abstract
The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.
Links
LO1214, research and development projectName: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 2/8/2024 04:29